A systematic review of the effectiveness of adalimumab

96
Health economics
p remaining
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 20 40 60 80 100
Weeks on treatment
FIGURE 48 Illustrative curve for survival time on a treatment (based on leflunomide data)
TABLE 44 Early cessation of DMARDs: data, sources and comments
Drug Cessation at Ceasing between Comments and source
≤ 6 weeks a 6 and 24 weeks
Adal (with or 5% 10% (5% because of No appropriate data found; assume same as infliximab
without MTX) toxicity and 4% for
inefficacy, 1% for other
reasons)
AZA 15% 25% Data estimated from Willkens. 181 Reasons for cessation
due to toxicity, inefficacy or other reasons are not available
CyA 8% 24% (12% because of Data estimated from Yocum182 It is assumed that half
inefficacy and 12% of those ceasing between 6 and 24 weeks do so because
for toxicity) of inefficacy and the other half because of toxicity; based
on observations by Marra. 183
Etan (with or 4% 3% (1% because of Observational study by Geborek 2002 171 (see leflunomide).
without MTX) toxicity and 2% for
inefficacy)
84% of all patients remained on treatment at 12 months
GST 14% 27% (18% because of Figures estimated from Hamilton. 184 Estimated figures
toxicity and 9% for from Zeidler 175 are 10% within 6 weeks and 34% at
inefficacy) 24 weeks
HCQ 3% 18% (4% because of Data estimated from Furst185 using a cohort treated with
toxicity and 14% for 800 mg per day as this group provided the most complete
inefficacy) data set
Infl + MTX 5% 10% (5% because of Observational study by Geborek 171 (see leflunomide).
toxicity and 4% for
inefficacy, 1% for
other reasons)
75% of all patients remained on treatment at 12 months
LEF 10% for drug 30% (10% because of Data estimated from Geborek. 171 These data are preferred
toxicity and toxicity, 19% for to trial data because clinical experience indicates that
3% for other inefficacy and 1% for continued drug use is less likely in practice than use in
reasons other reasons) randomised trials. 186
MTX 8.5% 19.5% (8.5% because Estimates from Hamilton 184
of toxicity and 11% for
inefficacy)
continued